Drug-Eluting Stents: Issues of Late Stent Thrombosis

Cardiology Clinics

Volumn 28, Issue 1, 2010, Pages 97-105

  Lemesle, Gilles ^a   Maluenda, Gabriel ^a   Collins, Sara D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Drug eluting stent; Percutaneous coronary intervention; Stent thrombosis

Indexed keywords

CLOPIDOGREL; EVEROLIMUS; POLYMER; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; ZOTAROLIMUS;

BARE METAL STENT; CLINICAL STUDY; CLINICAL TRIAL; DRUG ELUTING STENT; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SAFETY; STENT THROMBOSIS;

CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; INCIDENCE; RISK FACTORS; TIME FACTORS;

EID: 70649100417     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2009.09.003     Document Type: Review

References (57)

1. Morice M.C., Serruys P.W., Barragan P., et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 50 (2007) 1299-1304
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Stone G.W., Ellis S.G., Cox D.A., et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 (2004) 1942-1947
4. Weisz G., Leon M.B., Holmes Jr. D.R., et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 47 (2006) 1350-1355
5. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455 [discussion: 1455]
6. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
7. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
8. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
9. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
10. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
11. Mauri L., Hsieh W.H., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
12. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
13. Spaulding C., Daemen J., Boersma E., et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
14. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
15. Bavry A.A., Kumbhani D.J., Helton T.J., et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
16. Ellis S.G., Colombo A., Grube E., et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 49 (2007) 1043-1051
17. Jensen L.O., Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50 (2007) 463-470
18. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
19. Pinto Slottow T.L., Steinberg D.H., Roy P.K., et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol 102 (2008) 298-303
20. Vaknin-Assa H., Assali A., Ukabi S., et al. Stent thrombosis following drug-eluting stent implantation. A single-center experience. Cardiovasc Revasc Med 8 (2007) 243-247
21. Holmes Jr. D.R., Moses J.W., Schofer J., et al. Cause of death with bare metal and sirolimus-eluting stents. Eur Heart J 27 (2006) 2815-2822
22. Marzocchi A., Saia F., Piovaccari G., et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 115 (2007) 3181-3188
23. Shishehbor M.H., Goel S.S., Kapadia S.R., et al. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J Am Coll Cardiol 52 (2008) 1041-1048
24. Fajadet J., Wijns W., Laarman G.J., et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114 (2006) 798-806
25. Kandzari D.E., Leon M.B., Popma J.J., et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48 (2006) 2440-2447
26. Leon M.B. Endeavor IV: a randomized comparison of a Zotarolimus-eluting stent and a Paclitaxel-eluting stent in patients with coronary artery disease (2007), TCT Congress, Washington, DC. Available at: http://www.tctmd.com/Show.aspx?id=7700 Accessed March 1, 2009
27. Lassen J. SORT OUT III: a prospective randomized comparison of Zotarolimus-eluting and Sirolimus-eluting stents in patients with coronary artery disease (2008), TCT Congress, Washington, DC. Available at: http://www.crtonline.org/flash.aspx?PAGE_ID=5820 Accessed March 1, 2009
28. Thuesen L. Western Denmark Heart Registry: large-scale registry examining safety and effectiveness of Zotarolinus-eluting and Sirolimus-eluting stents in patients with coronary artery disease (2008), TCT Congress, Washington, DC. Available at: http://www.crtonline.org/flash.aspx?PAGE_ID=5818 Accessed March 1, 2009
29. Serruys P.W., Ruygrok P., Neuzner J., et al. A randomized comparison of an everolimus-eluting stent with a paclitaxel-eluting stent: the SPIRIT II trial. EuroIntervention 2 (2006) 286-294
30. Stone G.W., Midei M., Newman W., et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents. Two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 119 5 (2009) 680-686
31. Stone G.W., Midei M., Newman W., et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299 (2008) 1903-1913
32. de la Torre-Hernandez J.M., Alfonso F., Hernandez F., et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 51 (2008) 986-990
33. Park D.W., Park S.W., Park K.H., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356
34. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
35. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
36. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
37. Cook S., Wenaweser P., Togni M., et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115 (2007) 2426-2434
38. Jeremias A., Sylvia B., Bridges J., et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109 (2004) 1930-1932
39. Silber S., Albertsson P., Aviles F.F., et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26 (2005) 804-847
40. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) 216-235
41. Stone G.W., Ellis S.G., Colombo A., et al. Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data). Am J Cardiol 102 (2008) 1017-1022
42. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007) 745-754
43. De Luca G., Cassetti E., and Marino P. Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials. J Thromb Thrombolysis 27 4 (2008) 365-378
44. Farb A., Burke A.P., Kolodgie F.D., et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
45. Lemesle G., Delhaye C., Bonello L., et al. Stent thrombosis in 2008: Definition, predictors, prognosis and treatment. Arch Cardiovasc Dis 101 (2008) 769-777
46. Kereiakes D.J., Choo J.K., Young J.J., et al. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med 5 (2004) 9-15
47. Cutlip D.E., Baim D.S., Ho K.K., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001) 1967-1971
48. Orford J.L., Lennon R., Melby S., et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 40 (2002) 1567-1572
49. Lemesle G., Sudre A., Modine T., et al. High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. Catheter Cardiovasc Interv 72 (2008) 470-478
50. Wenaweser P., Rey C., Eberli F.R., et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 26 (2005) 1180-1187
51. Lemesle G., de Labriolle A., Bonello L., et al. Clinical manifestation and prognosis of early- versus late stent thrombosis of drug-eluting stents. J Interv Cardiol 22 (2009) 228-233
52. Nakae I., Fujita M., Fudo T., et al. Relation between preexistent coronary collateral circulation and the incidence of restenosis after successful primary coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 27 (1996) 1688-1692
53. Newman P.E. The coronary collateral circulation: determinants and functional significance in ischemic heart disease. Am Heart J 102 (1981) 431-445
54. Sabri M.N., DiSciascio G., Cowley M.J., et al. Coronary collateral recruitment: functional significance and relation to rate of vessel closure. Am Heart J 121 (1991) 876-880
55. Nathoe H.M., Koerselman J., Buskens E., et al. Determinants and prognostic significance of collaterals in patients undergoing coronary revascularization. Am J Cardiol 98 (2006) 31-35
56. Gerber R., and Colombo A. Does IVUS guidance of coronary interventions affect outcome? A prime example of the failure of randomized clinical trials. Catheter Cardiovasc Interv 71 (2008) 646-654
57. Roy P., Steinberg D.H., Sushinsky S.J., et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur Heart J 29 (2008) 1851-1857